Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB Vaccine (CHA Vaccine Research Institute) is an experimental boosting vaccine currently in the preclinical feasibility stage for the prevention of tuberculosis. Developed by the CHA Vaccine Research Institute, the vaccine is specifically designed as a 'boosting vaccine' to enhance anti-Mycobacterium tuberculosis immunity, likely intended for use in individuals previously primed with the BCG vaccine. The development program leverages the institute's expertise in proprietary adjuvant systems to stimulate a robust and lasting immune response against the pathogen. As of the latest pipeline update, the candidate is undergoing feasibility studies to determine its potential for clinical advancement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TB Vaccine (CHA Vaccine Research Institute).